Goldman Sachs
PETX

Goldman Sachs’s Aratana Therapeutics, Inc. PETX Stock Holding History

Goldman Sachs’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-821,902
Closed -$4.24M – 5547
2019
Q2 		$4.24M Buy
821,902
+764,730
+1,338% +$3.44M ﹤0.01% 2961
2019
Q1 		$206K Sell
57,172
-296,789
-84% -$1.29M ﹤0.01% 4785
2018
Q4 		$2.17M Sell
353,961
-254,831
-42% -$1.56M ﹤0.01% 3478
2018
Q3 		$3.56M Buy
608,792
+491,351
+418% +$2.45M ﹤0.01% 3226
2018
Q2 		$499K Sell
117,441
-435,342
-79% -$2.19M ﹤0.01% 4504
2018
Q1 		$2.44M Buy
552,783
+484,744
+712% +$2.16M ﹤0.01% 3455
2017
Q4 		$358K Buy
68,039
+17,677
+35% +$108K ﹤0.01% 5063
2017
Q3 		$309K Buy
50,362
+15,528
+45% +$98.3K ﹤0.01% 5447
2017
Q2 		$252K Sell
34,834
-30,581
-47% -$188K ﹤0.01% 5640
2017
Q1 		$347K Buy
65,415
+5,165
+9% +$34.9K ﹤0.01% 5338
2016
Q4 		$433K Sell
60,250
-20,807
-26% -$168K ﹤0.01% 5182
2016
Q3 		$759K Buy
81,057
+55,830
+221% +$464K ﹤0.01% 4663
2016
Q2 		$159K Buy
25,227
+10,713
+74% +$68.9K ﹤0.01% 5856
2016
Q1 		$80K Sell
14,514
-38,831
-73% -$146K ﹤0.01% 6193
2015
Q4 		$298K Buy
53,345
+43,091
+420% +$285K ﹤0.01% 5359
2015
Q3 		$87K Buy
+10,254
New +$174K ﹤0.01% 6564
2015
Q1 		– Sell
-293,709
Closed -$5.23M – 7396
2014
Q4 		$5.23M Sell
293,709
-24,363
-8% -$304K ﹤0.01% 2958
2014
Q3 		$3.19M Buy
318,072
+15,965
+5% +$194K ﹤0.01% 3462
2014
Q2 		$4.72M Sell
302,107
-16,285
-5% -$231K ﹤0.01% 3110
2014
Q1 		$5.91M Buy
318,392
+283,049
+801% +$5.67M ﹤0.01% 2833
2013
Q4 		$675K Sell
35,343
-32,547
-48% -$661K ﹤0.01% 5074
2013
Q3 		$1.11M Buy
+67,890
New +$713K ﹤0.01% 4511

Other funds holding PETX

DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return
ASN
Advisory Services Network Atlanta, Georgia $7.52B AUM 29.01% 1-Year Est. Return

Goldman Sachs's PETX Position: Q3 2019 in Review

Goldman Sachs sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2019, closing a stake of 821,902 shares — an estimated $4.24M sold.

Goldman Sachs first reported a position in PETX in Q3 2013 and held it in 22 quarters. The position peaked at $5.91M in Q1 2014. 2 funds tracked by Wall St. Rank hold PETX as of Q3 2019.

  • Goldman Sachs reported no remaining Aratana Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Goldman Sachs sold 821,902 Aratana Therapeutics, Inc. shares in Q3 2019, an estimated $4.24M.
  • Goldman Sachs first reported a position in Aratana Therapeutics, Inc. in Q3 2013 and held it in 22 quarters.
  • Goldman Sachs's Aratana Therapeutics, Inc. position peaked at $5.91M in Q1 2014.
  • 2 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2019.

Based on Goldman Sachs's 13F filing for Q3 2019, filed 14 Nov 2019.